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Despite preventive guidelines, iatrogenic contrast-induced nephro-
pathy (CIN) ranks third as a cause of hospital-acquired AKI, impacts 
significantly on morbidity and mortality, and is associated with 
longer stays in hospitals, with higher medical costs.[1-4] 
The rates of CIN vary, depending on the study definitions 
employed and underlying risk factors, and range from 0.6% to 30% 
or higher among risk groups.[5-8] CIN is also associated with increased 
duration of hospitalisation and early and late mortality. In-hospital 
mortality due to CIN ranges from 7% to 22%.[9] McCullough et 
al.[9] reported early mortality of 1.1% in controls, 7.1% in CIN 
patients, and 35% in CIN patients that required dialysis. Owing to 
increased comorbidities, hospitalised patients have increased risk for 
developing CIN compared with ambulatory patients.[10] 
Inflammation and endothelial dysfunction, together with reactive 
oxygen species (ROS), are implicated in the pathogenesis of CIN.[8] 
Iodinated contrast media directly injures the renal tubular epithelium by 
producing ROS radicals that cause intra-renal vasoconstriction leading to 
ischaemia and death of tubular cells.[8,10,11] Serum albumin is an important 
antioxidant that reduces the formation of oxygen free radicals and is 
important in expanding intravascular volume.[12,13] However, the role of 
serum albumin in reducing the incidence of CIN remains unexplored.
Sub-Saharan Africa has a dearth of data on rates of CIN. This study 
investigated the rates of CIN together with the influence of serum 
albumin, albuminuria, age, haemoglobin, and glomerular filtration 
rate (GFR) levels on CIN and patient outcomes. 
Methods 
Study design, setting and population 
This study was a prospective observational study conducted at 
Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, 
South Africa, from 1 July 2014 to 30 July 2015. Ethical approval was 
obtained from the human research ethics committee (HREC) of the 
University of the Witwatersrand and informed written consent was 
obtained from all patients. We consecutively recruited hospitalised 
patients undergoing computed tomography (CT) and angiography 
from the Divisions of Radiology and Cardiology, respectively. The 
following exclusion criteria were used: <18 years of age; evidence 
of pre-existing AKI (clinical or laboratory); end-stage renal disease 
(ESRD); renal replacement therapy (RRT); prior contrast media 
administration in the preceding 7 days; pregnancy; or incomplete data.
Study procedures
The study physician reviewed participants’ medical records and 
examined the participants in order to determine pre-existing risk 
factors for CIN. The medical records were reviewed to determine 
patient duration of hospitalisation, dialysis requirements and 
mortality. Study phlebotomists collected blood samples prior to and 
post contrast media administration. Pre contrast, urine was collected 
and analysed for microalbuminuria using the Chemistrip Micral 
30 immune assay test (Roche 11544039172). Serum creatinine was 
analysed using the Jaffe method (Siemens ADVIA 1200 chemistry 
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Background. Despite ranking third as a cause of hospital-acquired acute kidney injury (AKI), iatrogenic contrast-induced nephropathy 
(CIN) impacts significantly on morbidity and mortality and is associated with high hospital costs. In sub-Saharan Africa, the rates and risk 
factors for CIN and patient outcomes remain unexplored.
Methods. We conducted a prospective observational study at the Charlotte Maxeke Johannesburg Academic Hospital, South Africa, from 
1 July 2014 to 30 July 2015. Hospitalised patients undergoing computed tomography scan contrast media administration and angiography 
were consecutively recruited to the study and followed up for development of AKI. CIN was defined as an increase in serum creatinine 
>25% or an absolute increase of >44 µmol/L from baseline at 48 - 72 hours post exposure to contrast media. Outcome variables were the 
occurrence of CIN, length of hospitalisation and in-hospital mortality. 
Results. We recruited 371 hospitalised patients with a mean (standard deviation) age of 49.3 (15.9). The rates of CIN, assessed using an absolute or 
relative increase in serum creatinine from baseline, were 4.6% and 16.4%, respectively. Anaemia was an independent predictor for the development 
of CIN (risk ratio (RR) 1.71, 95% confidence interval (CI) 1.01 - 2.87; p=0.04). The median serum albumin was 34 g/L (interquartile range (IQR) 
29 - 39.5) and 38 g/L (IQR 31 - 42) in the CIN and control groups, respectively (p=0.01), and showed a significant trend for CIN development 
(RR 1.68, 95% CI 0.96 - 2.92; p=0.06). Mortality was significantly increased in the CIN group (22.4% v. 6.8%; p<0.001), and CIN together with 
anaemia increased mortality twofold (RR 2.39, 95% CI 1.20 - 4.75; p=0.01) and threefold (RR 3.32, 95% CI 1.48 - 7.43; p=0.003), respectively. 
Conclusions. CIN has a relatively high incidence in sub-Saharan Africa and predicts poorer clinical outcomes. The presence of CIN and anaemia 
positively predicted mortality. Caution should be exercised in patients with hypoalbuminaemia and anaemia undergoing contrast media administration.
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system) and estimated GFR (eGFR) was calculated using the four 
variable CKD-EPI equation.[14] Iopamidol (Jopamiron 370, Axim 
Pharmaceuticals, Italy), a low osmolar contrast agent, was used in all 
CT scan and angiography procedures. 
Study outcome measures 
The primary endpoint was the occurrence of CIN, defined as a serum 
creatinine increase of >25% from baseline or an absolute  increase of 
44  µmol/L assessed within 48 - 72 hours post contrast media admini-
stration as per the 2011 updated European Society of Urogenital Radiology 
(ESUR) guidelines.[15-17] Several studies have used the ESUR definition. 
The secondary endpoints were death and duration of hospitali sation 
obtained from patient records. The CIN group was reviewed for 
renal recovery and progression to chronic kidney disease (CKD) at 3 
months following the contrast exposure.
Statistical analysis
Statistical analyses were performed using Stata version 13 software 
(Stata Inc., USA). 
Using conservative estimates for the prevalence of CIN, a minimum 
sample size of 323 was required to sufficiently power this study. 
Continuous variables are presented as means and standard deviations 
Table 1. Baseline characteristics for study participants
Characteristic* All (N=371) CIN− (n=310) CIN+ (n=310) p-value
Age (years), mean (SD) 49.3 (15.9) 48.7 (16.3) 52.1 (14.1) 0.11
Gender (male), n (%) 210 (43.4) 174 (56.1) 36 (59.0) 0.86
Diabetes mellitus, n (%) 48 (13.2) 42 (13.8) 6 (10.3) 0.48
HTN, n (%) 93 (25.8) 78 (25.7) 15 (25.9 0.98
Malignancy, n (%) 159 (42.9) 136 (43.9) 23 (37.8) 0.34
Cardiac disease, n (%) 56 (15.1) 45 (14.5) 11 (18.0) 0.48
Stable CKD, n (%) 13 (3.6) 9 (2.9) 4 (6.9) 0.13
Systolic BP (mmHg), median (IQR) 119 (109 - 130) 119 (109.5 - 130) 120 (106 - 132) 0.43
Diastolic BP (mmHg), median (IQR) 73 (66 - 83) 73 (65 - 82.5) 74 (68 - 84) 0.18
Hospitalisation (days), median (IQR) 11 (6 - 20) 11 (5 - 18) 15(8 - 23) 0.52
Mortality, n (%) 33 (9.3 ) 20 (6.8) 13 (22.4) <0.001
Prehydration, n (%) 38 (17.7) 28 (15.8) 10 (26.3) 0.12
N acetyl cysteine, n (%) 3 (0.8) 3 (1.0) 0 (0.0) 0.45
ACEI/ARBs, n (%) 69 (19.2) 59 (19.5) 10 (17.5) 0.73
Statins, n (%) 67 (18.6) 55 (18.2) 12 (20.7) 0.66
Diuretics, n (%) 70 (19.5) 55 (18.3) 15 (25.9) 0.18
Serum creatinine (µmol/L) 68 (53 - 85) 68.5 (54 - 84) 61 (52 - 89) 0.49
eGFR (mL/min/1.73 m2), median (IQR) 110.8 (89.5 - 134) 113.4 (89.9 - 134) 107 (89.5 - 133) 0.84
eGFR <60mL/min/1.73 m2), n (%) 13 (3.5) 10 (76.9) 3 (23.1) 0.43
Urea (mmol/L), median (IQR) 4.8 (3.6 - 6.3) 4.9 (3.5 - 6.3) 4.7 (4 - 6.7) 0.08
Microalbuminuria, n (%) 58 (38.1) 46 (36.8) 12 (44.4) 0.46
Serum albumin (g/L), median (IQR) 37 (30 - 41) 38 (31 - 42) 34 (29 - 39.5) 0.01
Serum albumin <35 g/L, n (%) 113 (41.0) 82 (37.4) 31 (55.4) 0.02
Hb (g/dL), median (IQR) 12.3 (9.8 - 14.3) 12.5 (10.1 - 14.4) 11 (9.3 - 13.4) 0.01
Anaemia† (Hb <11 g/dL), n (%) 117 (34.5) 89 (32.1) 28 (50.9) 0.01
White cell count (× 109/L), median (IQR) 8.1 (6.3 - 11.7) 7.9 (6.3 - 11.7) 8.6 (5.9 - 13.9) 0.70
CRP (mg/L), median (IQR) 25.5 (10 - 70) 25.5 (10 - 70) 55 (12 - 115) 0.15
HIV-positive, n (%) 74 (36.8) 61 (37.2) 13 (35.1) 0.58
Sodium (mmol/L), median (IQR) 139 (135 - 141) 139 (136 - 141) 138 (135 - 140) 0.17
Bicarbonate (mmol/L), median (IQR) 25 (22 - 27) 25 (22 - 27) 24 (20 - 26) 0.45
Phosphate (mmol/L), median (IQR) 1.1 (0.90 - 1.2) 1.10 (0.90 - 1.24) 1.00 (0.81 - 1.20) 0.10
Contrast volume (mL), mean (SD) 103.8 (39.9) 103.7 (37.3) 104.2 (51.8) 0.95
Contrast dose:CrCL ratio 0.88 (0.72 - 1.16) 0.87 (0.72 - 1.17) 0.94 (0.71 - 1.1) 0.31
Ejection fraction %, mean (SD) 63.1 (14.0) 63.1 (14.0) 59.1 (13.3) 0.31
CIN− = CIN absent; CIN+ = CIN present; SD = standard deviation; HTN = hypertension; BP = blood pressure; IQR = interquartile range; ACEI/ARBs = angiotensin-converting enzyme inhibitors/
blockers; Hb = haemoglobin; CRP = C-reactive protein; CrCL = creatinine clearance.
*Continuous variables are expressed as mean (SD) when normally distributed and as medians (IQR) otherwise. Categorical variables are expressed as frequency (%). Differences between the CIN+ 
and CIN− groups are analysed by a t-test when normally distributed, a Wilcoxon-Mann-Whitney test when non-normally distributed and a χ2 test when categorical. 
†Anaemia is defined as haemoglobin <11 g/dL. 
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when normally distributed, and as medians 
and interquartile ranges (IQRs) when non-
normally distributed. Categorical variables 
are presented as counts and frequencies. 
Comparisons between CIN-positive (CIN+) 
and CIN-negative (CIN−) groups were 
assessed using a t-test for normally distri-
buted continuous variables, a Wilcoxon 
rank sum test for non-normally distributed 
continuous variables and a Pearson χ2 test 
for categorical variables. p-values of <0.05 
were considered significant. Multivariate 
analyses examined the associations of CIN 
and mortality with various risk factors and a 
generalised linear regression model built to 
adjust for confounding effects.
Results
Baseline characteristics 
Participants’ baseline characteristics are 
repor ted in Table 1. After excluding 60 non-
eligible patients (Fig. 1), 371 participants 
remained in the study; 74.9% were black, 
18.9% white, 3.8% Indian and 2.4% of 
mixed race. Ages ranged from 18 to 92 years 
(mean (standard deviation) 49.3 (15.9)). 
The rate of CIN was 16.4% (61/371) when 
based on a 25% increase from baseline in 
serum creatinine and 4.6% when based 
on an absolute increase of >44  µmol/L. 
Baseline serum creatinine and GFR were 
not significantly different between the 
CIN and control groups; almost 97% had 
baseline GFR ≥60 mL/min/1.73 m2, while 
the remaining 3% had baseline GFR ranging 
from 42 to 59 mL/min/1.73 m2. Compared 
with the CIN-free group, CIN patients had 
significantly lower levels of baseline serum 
albumin and haemoglobin. 
Independent predictors of CIN
After adjusting for all possible confounders, 
anaemia was found to be a predictor for 
CIN. Also, low serum albumin was positively 
associated with CIN development (Table 2).
CIN and mortality
Both duration of hospitalisation and mor-
tality were higher in the CIN group but 
only mortality was significantly increased 
(p<0.001) (Fig. 2). None of the patients 
who developed CIN required dialysis. Non-
significant variables that included cardiac 
disease, malignancy, contrast volume and 
baseline eGFR and albumin were excluded 
in the final model. In multivariable analysis 
CIN and anaemia were positive predictors 
for mortality (Table 3). 
Discussion 
The present study demonstrated a rela tively 
high rate of CIN in hospitalised patients. 
Assessed for eligibility,
N=431 
Study participants,
n=371 
Excluded, n= 60
Not meeting inclusion
criteria, n=38
Missing lab data, n=22  
CIN positive,
n=61 
 Within 48 - 72 hours CIN negative,
n=310 
Recovered AKI,
n=36 
CKD,
n=5  
In-hospital
mortality,
n=13
Survived,
n=48
In-hospital
mortality,
n=20
Lost to follow-up, n=7
4 = not reachable
2 =declined  
1 = died   
At 3 months
Fig. 1. Flow chart of study participants.
Table 2. Independent predictors for CIN
 
 
Unadjusted Adjusted
RR 95% CI p-value RR 95% CI p-value
Age 1.01 0.99 - 1.02 0.14 1.00 0.99 - 1.03 0.89
Gender 1.04 0.66 - 1.66 0.86 1.37 0.82 - 2.29 0.22
Albumin level
(<35 g/dL)
1.60 1.00 - 2.56 0.05 1.68  0.96 - 2.92 0.06
Anaemia 0.89 0.81 - 0.98 0.025 1.71 1.01 - 2.87 0.04
Baseline eGFR  0.99 0.98 - 1.00  0.70
RR = risk ratio; CI = confidence interval.
*Variables included in the final model were age, gender, anaemia, and albumin. 
Table 3. Independent predictors for mortality 
  Unadjusted Adjusted
  RR 95% CI p-value RR 95% CI p-value
CIN 3.27 1.72 - 6.18 <0.0001 2.39 1.20 - 4.75 0.01*
Age 1.00 0.96 - 1.02 0.98 0.99 0.98 - 1.01 0.91
Anaemia 3.61 1.75 - 7.45 0.001 3.32 1.48 - 7.43 0.003*
Contrast medium dose 0.99 0.98 - 0.99 0.02 0.99 0.99 - 1.00 0.55
Gender 1.06 0.55 - 2.05 0.18 0.96 0.49 - 1.89 0.91
*Included in final model were age, gender, anaemia, contrast media volume and CIN.
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Furthermore, the development of CIN 
resulted in increased mortality and high-
lighted the association of CIN with poorer 
clinical outcomes. 
Our study showed a 16.4% rate of CIN, 
which was slightly higher than reported 
in most recent studies. The reported 
incidence of CIN is variable, depending 
on the study definitions employed and 
underlying risk factors, and ranges from 5% 
to 30% overall. [5-8,18,19] Recent observational 
studies have reported low rates of CIN 
among hospitalised patients.[20,21] Shams-
Eddin Taher[21] observed a 11.5% rate of 
CIN in patients undergoing percutaneous 
intervention (PCI) while Selistre et al.[20] 
reported a 14% incidence of CIN in patients 
undergoing contrast CT administration in 
Brazil. A randomised controlled trial (RCT) 
in the USA found a 16.1% incidence of 
CIN in patients undergoing PCI.[22] The 
heterogeneous study population, variable 
comorbidities and non-standardised preven-
tive prescriptions used by clinicians may 
explain the high rate of CIN in our study.
In this study, CIN patients had signifi-
cantly lower levels of precontrast serum 
albumin compared with controls and showed 
a significant positive trend towards the 
development of CIN with serum albumin 
levels. Serum albumin is an important reno-
protective, anti-inflammatory and antioxidant 
agent acting via several mechanisms; serum 
albumin binds non-ceruloplasmin copper and 
iron, which are important in the formation 
of ROS, and maintains renal perfusion by 
dilating renal vessels via its binding to nitro-
gen oxide, forming S-nitro-albumin.[12,23- 26] 
However, during inflammation, albumin 
synthesis is reduced and activated neutrophils 
increase the levels of hypochlorous acid, 
which inactivates albumin.[12,13,23] Low serum 
albumin is probably a biomarker reflecting 
baseline susceptibility to acute or chronic 
inflammation or undernutrition. In two 
previous studies, Murat et al. [23] and Song et 
al. [24] found a positive association between 
low serum albumin and an increased risk 
for the development of CIN. A meta-analysis 
showed a positive association between 
decreased serum albumin and development 
of AKI, as well as increased morbidity and 
mortality.[27] The odds of developing AKI 
doubled with reduced serum albumin.[26] Lee 
et al.[28] reported twofold odds of developing 
postoperative AKI with decreased serum 
albumin. 
Of interest in our study was the impact 
of baseline anaemia on patient outcomes. 
The rate of baseline anaemia was relatively 
high in our study population compared 
with controls, and was associated with 
development of CIN and a threefold mor-
tality risk. Limited studies have explored 
the association of anaemia with CIN and 
patient outcomes. Li et al.[26] and Chong 
et al.[29] in observational studies reported 
a positive association between baseline 
anaemia and CIN. In these studies the pres-
ence of anaemia was associated with an 
almost twofold risk of developing CIN. [26,29] 
In patients undergoing PCI, Mckechnie et 
al.[30] similarly reported baseline anaemia 
as an independent predictor for mortality. 
The increased risk of CIN in patients with 
anaemia and poorer clinical outcomes is 
multifactorial in aetiology; in the presence of 
anaemia, CIN-induced renal ischaemia and 
hypoxia are significantly worsened in the 
outer renal medulla amid already prevailing 
low oxygen tension, and oxygen affinity and 
demand are increased.[26,31,32] Anaemia also 
signifies underlying comorbidities; therefore 
it is a biomarker for severity of disease at the 
time of contrast media administration, and 
increased mortality risk.[26,30] 
Age, baseline renal function (determined 
by eGFR) and prehydration were not asso-
ciated with the prevention of CIN in our 
study. The positive association between 
CIN and age has been shown in the age 
group above 62 years.[11] An RCT found 
age above 75 years together with diabetes 
mellitus to be a predictor for CIN.[22] In 
younger type 2 diabetic patients undergoing 
PCI, Zaki et al.[25] reported age above 57 
years to be a positive predictor for CIN. 
Our study population was relatively young, 
and fewer of our patients had multivessel 
disease compared with previous studies. 
Baseline eGFR level was insignificantly 
associated with CIN in our study cohort. 
Previous studies have shown decreased risk 
of developing CIN with eGFR >60 mL/
min/1.73 m2.[20] In an observational study, 
Weisbord et al.[33] found <1% incidence of 
CIN in patients with eGFR >45 - 60 mL/
min/1.73 m2 after contrast administration. 
In support of our study, Chong et al.[29] 
found insignificant association between 
normal renal status and CIN development. 
In a cohort study of 80% study participants 
with eGFR >60 mL/min/1.73 m2, Selistre et 
al.[20] also reported no association between 
baseline eGFR and risk for CIN. In our 
study cohort, 97% of study participants had 
normal baseline renal function based on 
eGFR, with the remaining having eGFR 
ranging from 42 to 59 mL/min/1.73 m2 with 
no significant association with CIN. 
Prehydration therapy was used in only 
18% of patients in our study cohort com-
pared with 70% seen in developed coun-
tries,[34] and prehydration showed no impact 
on reducing the incidence of CIN. It is pos-
sible that only the patients at highest risk for 
CIN received prehydration and this possibly 
obscured any beneficial effects. In previous 
studies, Selistre et al.[20] observed no associa-
tion between fluid administration and CIN 
occurrence. Diogo et al.[35] reported a low 
rate of prehydration therapy in Brazil.
Similar to previous findings, our study 
demonstrated a higher mortality in the CIN 
group compared with controls, and CIN and 
anaemia were independent predictors of 
mortality.[36] Rihal et al.,[37] in a retrospective 
registry review at the Mayo Clinic, reported 
in-hospital mortality rates of 22.0% and 1.4% 
in the CIN and controls groups, respectively, 
and CIN was positively associated with a 
10-fold increased risk of death. Furthermore, 
cardiac disease was associated with a twofold 
increased risk of death. Sadeghi et al. [36,38] 
in a multicentre study found that 30-day 
mortality was significantly higher among 
patients with CIN compared with controls 
(16.2% v. 1.2%; p<0.001). In-hospital mor-
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Fig. 2. Contrast-induced nephropathy and mortality (CIN– v. CIN+, p<0.001).
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tality due to CIN in the National Cardiovascular Registry in USA was 
reported as 9.1%.[39]
Development of CIN also reflects underlying disease comorbidities 
at the time of contrast media administration. Despite increased 
mortality in the CIN group compared with controls, Sadeghi et 
al.[38] found underlying cardiac disease as a positive predictor for 
mortality. In other studies, age, cardiac disease and the requirement 
of dialysis were predictors for mortality in CIN participants.[36] In our 
study, among the 13 deaths in the CIN group, 7 had a diagnosis of 
malignancy; however, after adjusting for possible confounders, only 
CIN and anaemia (and not malignancy) were predictors of mortality. 
The strength of our study is that it was a prospective cohort with 
a large sample size. However, it is limited by being a single-centre, 
non-interventional study conducted at a tertiary hospital. The study 
consisted of a heterogeneous population, and prevention guidelines 
for CIN were not standardised or uniformly implemented.
Conclusion 
Our study highlights the high rates of CIN and associated poorer 
clinical outcomes. Caution should be used when administering 
iodinated contrast media to patients with hypoalbuminaemia and 
anaemia. To our knowledge, this is the first prospective study 
examining the risk and outcomes of CIN in sub-Saharan Africa. This 
study advocates that preventive treatment guidelines for CIN should 
be highlighted and standardised across various hospital departments.
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